First Time Loading...
T

TOT BIOPHARM International Co Ltd
HKEX:1875

Watchlist Manager
TOT BIOPHARM International Co Ltd
HKEX:1875
Watchlist
Price: 1.87 HKD Market Closed
Updated: May 13, 2024
Section:
 

Relative Value

The Relative Value of one TOT BIOPHARM International Co Ltd stock under the Base Case scenario is 4.04 HKD. Compared to the current market price of 1.87 HKD, TOT BIOPHARM International Co Ltd is Undervalued by 54%.

Relative Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.

Relative Value
Base Case
4.04 HKD
Undervaluation 54%
Relative Value
Price
T
Worst Case
Base Case
Best Case

Valuation Multiples

1.7
P/S
P/S
Price to Sales
1.7
vs History
44
vs Industry
83
Median 3Y
2.7
Median 5Y
1.5
Industry
8.2
Forward
1.8
More Details
Negative
P/E
P/E
Price to Earnings
N/A
vs History
vs Industry
Median 3Y
-30.1
Median 5Y
-34.3
Industry
27.4
Forward
84.8
More Details
14.3
P/OCF
P/OCF
Price to OCF
14.3
vs History
21
vs Industry
10
Median 3Y
-9.4
Median 5Y
-30.8
Industry
24.3
More Details
Negative
P/FCFE
P/FCFE
Price to FCFE
N/A
vs History
vs Industry
Median 3Y
-18.8
Median 5Y
-263.4
Industry
23
More Details
1.9
P/B
P/B
Price to Book Value
1.9
vs History
75
vs Industry
47
Median 3Y
3.8
Median 5Y
2.9
Industry
2.6
More Details
1.6
EV/S
EV/S
Enterprise Value to Sales
1.6
vs History
44
vs Industry
72
Median 3Y
2.4
Median 5Y
1.4
Industry
7.5
Forward
1.7
More Details
2.2
EV/GP
EV/GP
Enterprise Value to Gross Profit
2.2
vs History
44
vs Industry
69
Median 3Y
3.1
Median 5Y
1.9
Industry
9.3
More Details
Negative
EV/EBITDA
EV/EBITDA
Enterprise Value to EBITDA
N/A
vs History
vs Industry
Median 3Y
-50.4
Median 5Y
-4 736.5
Industry
4.3
Forward
18.8
More Details
Negative
EV/EBIT
EV/EBIT
Enterprise Value to EBIT
N/A
vs History
vs Industry
Median 3Y
-31.1
Median 5Y
-57.5
Industry
4.2
Forward
102
More Details
13.8
EV/OCF
EV/OCF
Enterprise Value to OCF
13.8
vs History
17
vs Industry
11
Median 3Y
-8.9
Median 5Y
-29
Industry
5.9
More Details
Negative
EV/FCFF
EV/FCFF
Enterprise Value to FCFF
N/A
vs History
vs Industry
Median 3Y
-6.8
Median 5Y
-8.9
Industry
3.3
More Details
1.7
EV/IC
EV/IC
Enterprise Value to IC
1.7
vs History
60
vs Industry
52
Median 3Y
2.4
Median 5Y
2.4
Industry
4.9
More Details

Multiples Across Competitors

Competitors Multiples
TOT BIOPHARM International Co Ltd Competitors

All Multiples
P/S
P/E
EV/EBITDA
EV/EBIT
All Countries
All Countries
Close
Market Cap P/S P/E EV/EBITDA EV/EBIT
CN
TOT BIOPHARM International Co Ltd
HKEX:1875
1.4B HKD 1.7 -35.4 -59.7 -59.7
US
Abbvie Inc
NYSE:ABBV
283.9B USD 5.2 58.9 12.8 19.5
US
Amgen Inc
NASDAQ:AMGN
166.4B USD 5.6 44.2 18.6 30.7
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
108.9B USD 11 30.1 24.2 25.4
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
107.3B USD 8.2 27.8 22.5 24.9
AU
CSL Ltd
ASX:CSL
134.9B AUD 6.3 36 21.8 27
US
Gilead Sciences Inc
NASDAQ:GILD
82.2B USD 3 169.8 6.8 8.9
US
Moderna Inc
NASDAQ:MRNA
44.9B USD 8.7 -7.5 -8.1 -7.2
US
Seagen Inc
NASDAQ:SGEN
43.1B USD 18.8 -57.5 -61.9 -55.8
US
Biogen Inc
NASDAQ:BIIB
32.3B USD 3.3 27.6 14.1 17.7
KR
Celltrion Inc
KRX:068270
40T KRW 18.4 74.6 45.6 62.9
EV/EBITDA Multiple
EBITDA Growth
CN
T
TOT BIOPHARM International Co Ltd
HKEX:1875
Average EV/EBITDA: 20.8
Negative Multiple: -59.7 		N/A
US
Abbvie Inc
NYSE:ABBV
12.8
26%
US
Amgen Inc
NASDAQ:AMGN
18.6
62%
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
24.2
59%
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
22.5
50%
AU
CSL Ltd
ASX:CSL
21.8
54%
US
Gilead Sciences Inc
NASDAQ:GILD
6.8
18%
US
Moderna Inc
NASDAQ:MRNA
Negative Multiple: -8.1 N/A
US
Seagen Inc
NASDAQ:SGEN
Negative Multiple: -61.9 N/A
US
Biogen Inc
NASDAQ:BIIB
14.1
67%
KR
Celltrion Inc
KRX:068270
45.6
109%

See Also

Summary
Intrinsic value, competitors valuation, and company profile.
DCF Valuation
Stock valuation using Discount Cash Flow valuation method.
Relative Valuation
Stock valuation using valuation multiples.
Wall Street Estimates
Price targets and financial estimates made by Wall st analysts.
Profitability Analysis
Detailed analysis of the company's profitability.
Solvency Analysis
Analysis of the financial position and solvency of the company.
Financials
Income Statement, Balance Sheet, Cash Flow Statement.
Discount Rate
Stock discount rate: cost of equity and WACC.
Summary
DCF Valuation
Relative Valuation
Wall Street Estimates
Profitability Analysis
Solvency Analysis
Financials
Discount Rate
Discover More
ALPHA SPREAD
Join more than 136,700+ value investors using Alpha Spread
Create a free account
or see our plans & pricing

Company

About Us Careers Pricing Affiliate Program Terms of Service Privacy Policy

Help

What is Intrinsic Value? Help Center Contact Us

Tools

Stock Screener Intrinsic Value Calculator DCF Value Calculator Discount Rate Calculator

Stocks

Most Undervalued Stocks High Profitability Stocks High Solvency Stocks Most Popular Stocks

© 2024 Alpha Spread Limited. All Rights Reserved.

www.alphaspread.com is not operated by a broker, a dealer, or a registered investment adviser. Under no circumstances does any information posted on www.alphaspread.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute, investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. In no event shall Alpha Spread Limited be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on www.alphaspread.com, or relating to the use of, or inability to use, www.alphaspread.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance.